

# Optimizing Pharmacotherapy in Depressive Patients With Residual Symptoms

Registration and Breakfast

6:00 a.m. – 7:00 a.m.

Satellite Symposium

7:00 a.m. – 9:00 a.m.

## Location:

Hilton Anaheim  
Pacific Ballroom B

## Program Overview:

Treatment resistant depression is a major and increasing health burden to individuals and to society. Depression treatment should be guided by evidence-based research and tailored for the individual patient through the routine measurement of symptoms, adverse effects, and functioning, so as to optimize the sequential treatment approaches. Pharmacists practicing pharmaceutical care are perfectly suited to assist physicians in identifying optimal pharmacotherapy and improving medication-related outcomes.

Members of the American College of Clinical Pharmacy (ACCP) are at the forefront of clinical pharmacy and are influential in promoting safe and effective pharmaceutical care for patients with depression. More than 70% of ACCP members directly influence health system formularies and protocol-based drug decision-making, and more than 90% teach physicians and other health professionals about appropriate pharmacotherapy. Educating clinical pharmacists that are influential in the practice of the pharmacy profession, as well as influential in pharmacotherapy choice to clinicians and policymakers in various health systems, will result in improved treatment and follow-up of patients with depression that ultimately improves outcomes.

## Educational Objectives:

At the conclusion of this activity, participants should be able to:

- **Describe** current approaches to optimize remission from depression;
- **Discuss** the evidence and rationale for switching versus augmentation/combined therapy approaches;
- **Implement** a pharmaceutical care plan in the monitoring and management of potential medication-related problems; and
- **Discuss** the role of pharmacist in the multidisciplinary collaborative approach to improving care of patients with depression.

## Agenda & Faculty:

6:00 a.m. – 7:00 a.m.	Registration and Breakfast Seating
7:00 a.m. – 7:10 a.m.	Introductory Remarks: Treating to Remission <i>Patrick R. Finley, Pharm.D., BCPP</i>
7:10 a.m. – 7:40 a.m.	Pharmacotherapeutic Strategies in Treating to Remission <i>Charles DeBattista, DMH, M.D.</i>
7:40 a.m. – 8:10 a.m.	Monitoring of Efficacy and Potential Adverse Effects in Augmentation Approaches <i>Shannon J. Drayton, Pharm.D., BCPP</i>
8:10 a.m. – 8:40 a.m.	Expanding Role of Pharmacists in Care of Patients With Depression <i>Patrick R. Finley, Pharm.D., BCPP</i>
8:40 a.m. – 8:55 a.m.	Panel Discussion/Question & Answer Session
8:55 a.m. – 9:00 a.m.	Chair's Concluding Remarks & Adjournment

## Faculty:

### Charles DeBattista, DMH, M.D.

Associate Professor  
Psychiatry & Behavioral Sciences  
Director of Depression Research & Psychopharmacology Clinic  
Stanford University  
Stanford, California, USA

### Shannon J. Drayton, Pharm.D., BCCP

Assistant Professor  
Department of Pharmacy & Clinical Sciences  
South Carolina College of Pharmacy  
Medical University of South Carolina  
Charleston, South Carolina, USA

**Patrick R. Finley, Pharm.D., BCCP**

Professor of Clinical Pharmacy

Department of Clinical Pharmacy

University of California San Francisco, School of Pharmacy

San Francisco, California, USA

**Target Audience:**

This CE activity is intended for pharmacists and other healthcare professionals who have an interest in identifying and managing psychiatric patients with treatment resistant depression (TRD).

**Continuing Education Credit:**



The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The ACPE provider number is 447-999-09-075-C04-P. To receive the 2 contact hour of continuing education credit, 0.2 Continuing Education Units (CEUs), pharmacists should complete the activity requirements and evaluation at the conclusion of the activity.

This program is supported by an educational grant from Bristol-Myers Squibb and Otsuka America Pharmaceutical.

**Registration Information:**

There is no registration fee to attend this symposium.

To register for this symposium or if you have questions, please contact Jamie Miller, at (973) 560-1234 ext. 16 or via e-mail [jmiller@lets-ci.org](mailto:jmiller@lets-ci.org).